Methylphenidate in the treatment of female adolescents with cooccurrence of attention deficit/hyperactivity disorder and borderline personality disorder: a preliminary open-label trial
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Recent studies reported symptomatic overlap between attention deficit/hyperactivity disorder (ADHD) and borderline personality disorder (BPD). Methylphenidate (MPH) is the most efficient treatment for ADHD. We assessed the efficacy and tolerability of MPH treatment in adolescent females who met the Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV criteria for both disorders. Fourteen BPD/ADHD female adolescents aged 14-19 years were treated with MPH for 12 weeks, targeting ADHD, BPD symptoms, and aggressive behavior, as rated by ADHD-rating scale (ADHD-RS) and Clinical Global Impression-Severity (CGI-S) scale for BPD and aggressive behavior severity. A significant improvement was detected in both ADHD and BPD severity (baseline vs. end point, ADHD-RS: 33.1+/-4.8 vs. 17.6+/-5.2, P<0.001; BPD CGI-S: 4.6+/-0.8 vs. 3.4+/-0.8, P<0.0005, respectively) as well as in aggressive behavior (Aggression CGI-S: 3.5+/-1.3 vs. 1.8+/-0.5, P<0.001). MPH was well tolerated. MPH may be useful and well tolerated in treating some shared symptoms of ADHD and BPD among female adolescents. Controlled studies are needed to substantiate these findings.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Importantly, individuals presenting with a diagnosis of personality disorder who present with the ADHD syndrome that started in childhood will in many cases benefit from pharmacological treatments for ADHD [232,233].”
From European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD (2010) · cites this paper as [232]
Citations
Cites
KAUFMAN, J., BIRMAHER, B., BRENT, D., RAO, U., FLYNN, C., MORECI, P., WILLIAMSON, D., & RYAN, N. (1997) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199707000-00021 · Cited by 10,148 · cited 1×
“Psychiatric assessments for comorbidity were made with the Kiddie Schedule for Affective Disorders and Schizophrenia, epidemiologic version (Kiddie-SADS-PL), covering childhood DSM-IV diagnoses (Orvaschel, 1985; Kaufman et al., 1997).”
MethodBARKLEY, R. A., FISCHER, M., EDELBROCK, C. S., & SMALLISH, L. (1990) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199007000-00007 · Cited by 1,507 · cited 1×
“Attention deficit/hyperactivity disorder (ADHD) is the most prevalent neuropsychiatric disorder among children and adolescents, with prevalence rates ranging from 3 to 9% (Barkley et al., 1990; Spencer et al., 1999).”
Background(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.6.885 · Cited by 1,421 · cited 1×
“For this purpose, they used the Wender Utah Rating Scale (WURS), a 61-item scale for assessing adult ADHD that evaluates ADHD-relevant childhood behaviors and symptoms, retrospectively (Ward et al., 1993).”
MethodMethylphenidate improves response inhibition in adults with attention-deficit/hyperactivity disorder
Aron, A. R., Dowson, J. H., Sahakian, B. J., & Robbins, T. W. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00609-7 · Cited by 391 · cited 1×
“It is possible that the MPH-related improvement in executive function and behavioral inhibition (Aron et al., 2003) is relevant to the beneficial effect in both psychopathologies, despite the differences in core pathophysiology.”
BackgroundATTENTION-DEFICIT/HYPERACTIVITY DISORDER AND COMORBIDITY
Spencer, T., Biederman, J., & Wilens, T. (1999) · Pediatric Clinics of North America · doi:10.1016/s0031-3955(05)70163-2 · Cited by 270 · cited 2×
“Introduction Attention deficit/hyperactivity disorder (ADHD) is the most prevalent neuropsychiatric disorder among children and adolescents, with prevalence rates ranging from 3 to 9% (Barkley et al., 1990; Spencer et al., 1999).”
BackgroundPsychiatric interviews suitable for use in research with children and adolescents.
Orvaschel, H. (1985) · PubMed · Cited by 238
Philipsen, A. (2006) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-006-1006-2 · Cited by 184 · cited 1×
“A number of studies have assessed the relationships between BPD and ADHD, and most of them suggested symptomatic overlap between the two disorders (Dowson et al., 2004; Davids and Gastpar, 2005; Philipsen, 2006).”
BackgroundFossati, A., Novella, L., Donati, D., Donini, M., & Maffei, C. (2002) · Comprehensive Psychiatry · doi:10.1053/comp.2002.34634 · Cited by 182 · cited 1×
“In an attempt to identify the developmental childhood antecedents of BPD and other personality disorders, Fossati et al. (2002) examined the association between the history of childhood ADHD symptoms and diagnosis of BPD in adulthood.”
BackgroundRoss, R. G. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.7.1149 · Cited by 167 · cited 2×
“Despite caution regarding MPH treatment in BPD population, like possible development of addictive behavior for MPH or psychotic deterioration (Ross, 2006; Martin et al., 2007), only one case of psychotic exacerbation in personality disorder patients, treated with MPH, was previously described…”
BackgroundLAMPE, K., KONRAD, K., KROENER, S., FAST, K., KUNERT, H. J., & HERPERTZ, S. C. (2007) · Psychological Medicine · doi:10.1017/s0033291707000517 · Cited by 147 · cited 1×
“Frontocortical-mediated ‘response inhibition’ is a mechanism that may account for the beneficial effects of MPH on both, symptoms of ADHD and BPD, in these adolescent females (Lampe et al. 2007).”
Background
Research works printed but not linked: 2
- Hooberman, 1984, J Clin Psychiatry, 45, 441
- Orvaschel, 1985, Psychopharmacol Bull, 21, 737
Cited by
Kooij, S. J., Bejerot, S., Blackwell, A., Caci, H., Casas-Brugué, M., Carpentier, P. J., Edvinsson, D., Fayyad, J., Foeken, K., Fitzgerald, M., et al. (2010) · BMC Psychiatry · doi:10.1186/1471-244x-10-67 · Cited by 928
“Importantly, individuals presenting with a diagnosis of personality disorder who present with the ADHD syndrome that started in childhood will in many cases benefit from pharmacological treatments for ADHD [232,233].”
Top-Down Dysregulation—From ADHD to Emotional Instability
Petrovic, P., & Castellanos, F. X. (2016) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2016.00070 · Cited by 179
“…on emotional dysregulation behaviors in ASPD and CD (Kaplan et al., 1990; Brown et al., 1991; Klein et al., 1997; Connor et al., 2000) as well as BPD (Schulz et al., 1988; Golubchik et al., 2008; Prada et al., 2015; although see Schulz et al. (1988) for possible issue with schizotypal comorbidity).”
BackgroundAsherson, P., Young, A. H., Eich-Höchli, D., Moran, P., Porsdal, V., & Deberdt, W. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.915800 · Cited by 130
Matthies, S. D., & Philipsen, A. (2014) · Borderline Personality Disorder and Emotion Dysregulation · doi:10.1186/2051-6673-1-3 · Cited by 110
“A positive effect on self-injurious behavior was observed [95].”
BackgroundWeiner, L., Perroud, N. A., & Weibel, S. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s192871 · Cited by 105
Moukhtarian, T. R., Mintah, R. S., Moran, P., & Asherson, P. J. (2018) · Borderline Personality Disorder and Emotion Dysregulation · doi:10.1186/s40479-018-0086-8 · Cited by 61
“31) following treatment with methylphenidate for 12 weeks [105].”
MethodImpulsive aggression in adults with attention‐deficit/hyperactivity disorder
Dowson, J. H., & Blackwell, A. D. (2010) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2009.01460.x · Cited by 39
“However, although methylphenidate (MPH) has been reported to be effective in reducing impulsive aggression in subjects with ADHD when this is comorbid with BPD or CD and ⁄or ODD, this effect could just reflect a reduction in a nonspecific enhancement, by ADHD, of the impulsive aggression in the comorbid disorder (12,…”
BackgroundMethylphenidate and desipramine combined treatment improves PTSD symptomatology in a rat model
Aga‐Mizrachi, S., Cymerblit‐Sabba, A., Gurman, O., Balan, A., Shwam, G., Deshe, R., Miller, L., Gorodetsky, N., Heinrich, N., Tzezana, O., et al. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.82 · Cited by 47
Prada, P., Nicastro, R., Zimmermann, J., Hasler, R., Aubry, J., & Perroud, N. A. (2015) · ADHD Attention Deficit and Hyperactivity Disorders · doi:10.1007/s12402-015-0165-2 · Cited by 44
“Those studies showed that a proper treatment for ADHD improves the patient’s symptoms (van Reekum and Links 1994; Golubchik et al. 2008).”
BackgroundScreening for attention-deficit/hyperactivity disorder in borderline personality disorder
Weibel, S., Nicastro, R., Prada, P., Cole, P., Rüfenacht, E., Pham, E., Dayer, A. G., & Perroud, N. A. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.09.027 · Cited by 40
Avital, A., Dolev, T., Aga‐Mizrachi, S., & Zubedat, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022059 · Cited by 36
Association of pharmacological treatments and real‐world outcomes in borderline personality disorder
Lieslehto, J., Tiihonen, J., Lähteenvuo, M., Mittendorfer‐Rutz, E., Tanskanen, A., & Taipale, H. T. (2023) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13564 · Cited by 34
“Two open-label studies found that methylphenidate treatment in BPD was associated with reduced aggression, symptom severity, and impulsiveness.(41,42) Our results indicate that treating patients with BPD using stimulants is potentially effective.”
ResultTreatment of borderline personality disorder in youth.
Biskin, R. S. (2013) · Europe PMC (PubMed Central) · Cited by 39
Off-label use of atypical antipsychotics in personality disorders
Rosenbluth, M. J., & Sinyor, M. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.608351 · Cited by 26
“Another openlabel trial of methylphenidate for comorbid BPD and ADHD found that the stimulant reduced overall BPD symptoms and aggression [74].”
BackgroundMcQuade, J. D., Dixon–Gordon, K. L., Breaux, R., & Babinski, D. E. (2021) · Research on Child and Adolescent Psychopathology · doi:10.1007/s10802-020-00717-5 · Cited by 20
“The strong relation between childhood ADHD symptoms and adolescent BPD features suggests that evidence-based treatments that reduce ADHD symptoms may also reduce elevations in later BPD features (see Babinski et al., 2018; Golubchik et al., 2008).”
BackgroundBourvis, N., Cohen, D., & Benarous, X. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12206668 · Cited by 22
Gvirts, H. Z., Lewis, Y. D., Dvora, S., Feffer, K., Nitzan, U., Carmel, Z., Levkovitz, Y., & Maoz, H. (2018) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000219 · Cited by 14
EEG-vigilance regulation in Borderline Personality Disorder
Kramer, L., Sander, C., Bertsch, K., Gescher, D. M., Cackowski, S., Hegerl, U., & Herpertz, S. C. (2019) · International Journal of Psychophysiology · doi:10.1016/j.ijpsycho.2019.02.007 · Cited by 12
Golubchik, P., Sever, J. M., & Weizman, A. (2009) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181a5d075 · Cited by 9
“Some of the girls (6 of 12) were described in our earlier study on MPH in the treatment of female adolescents with cooccurrence of ADHD and BPD.27 In that study, the smoking behavior was monitored, and in the present study, we made use of the data that were collected and not reported on anywhere else.”
BackgroundInfluentialSelf-citationEvren, C., Karabulut, V., Alnıak, İ., Evren, B., Carkci, O. H., Cengel, H. Y., Menekseoglu, P. O., Cetin, T., Bozkurt, M., & Umut, G. (2019) · Psychiatry and Clinical Psychopharmacology · doi:10.1080/24750573.2019.1595271 · Cited by 7
“Although methylphenidate may be useful and well tolerated in treating some shared symptoms of ADHD andBPDamong female adolescents [115] and led to sig-”
BackgroundAddressing Borderline Personality Disorder in Females with ADHD
Babinski, D. E., & Waschbusch, D. A. (2021) · The ADHD Report · doi:10.1521/adhd.2021.29.1.1 · Cited by 3
Kooij, J. J. S. (2012) · Springer eBooks · doi:10.1007/978-1-4471-4138-9_2 · Cited by 3
Drugs to Treat Attention Deficit Hyperactivity Disorder (ADHD)
Müller, U., & Sedgwick-Müller, J. A. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623465.015 · Cited by 4
Kapoor, S. N. (2008) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2008.01290.x · Cited by 3
“another emerging treatment option that especially appears to be a better alternative for patients with concurrent attention deficit disorder (9).”
BackgroundRecent Developments in the Pharmacologic Management of Personality Disorders
Links, P. S., Boursiquot, P., & Links, M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108333931.087 · Cited by 2
Managing ADHD in Adolescence and Young Adulthood: Emerging Comorbidities and Tailored Treatment
Canales, I. E. (2012) · Humana Press eBooks · doi:10.1007/978-1-62703-248-3_9 · Cited by 2
Mashhadi, A., Soltani, E., Akbari, E., & Farmani, A. (2013) · Zahedan Journal of Research in Medical Sciences · Cited by 2
Wöckel, L., Goth, K., Zepf, F. D., Matic, N., Holtmann, M. H., Herpertz‐Dahlmann, B., & Poustka, F. (2010) · Praxis der Kinderpsychologie und Kinderpsychiatrie · doi:10.13109/prkk.2010.59.4.282 · Cited by 3
Kooij, J. J. S. (2021) · Springer eBooks · doi:10.1007/978-3-030-82812-7_4 · Cited by 2
Pardossi, S., Cuomo, A., Koukouna, D., Pinzi, M., Firenzuoli, B., & Fagiolini, A. M. (2025) · Life · doi:10.3390/life15030380 · Cited by 2
“Another study conducted in 14 adolescent patients with BPD-ADHD comorbidity treated with MPH demonstrated a global improvement in symptoms attributed to both ADHD and BPD, with an excellent tolerability profile [76].”
Kooij, J. J. S. (2012) · Springer eBooks · doi:10.1007/978-1-4471-4138-9_4 · Cited by 1
Kooij, J. J. S. (2021) · Springer eBooks · doi:10.1007/978-3-030-82812-7_2 · Cited by 1
METHYLPHENIDATE FOR BIPOLAR DEPRESSION
Mehmood, M. S. (2017) · The Professional Medical Journal · doi:10.17957/tpmj/17.4011
Rüesch, P., Altwicker-Hámori, S., & Juvalta, S. (2014) · Zürcher Hochschule für Angewandte Wissenschaften digital collection (Zurich University of Applied Sciences) · doi:10.21256/zhaw-1779 · Cited by 1
Current awareness in human psychopharmacology
(2008) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.971
Ellenberg, S., Pal, S., Cruz, L. D. L., Kidwai, F., & Ramanathan, S. (2024) · Personalized Medicine in Psychiatry · doi:10.1016/j.pmip.2024.100137
The Association Between Borderline Personality Disorder and Atypical Neurodevelopment
Gogne, A. (2025) · Springer eBooks · doi:10.1007/978-3-031-86588-6_6
Diagnose und Behandlung junger Menschen mit psychischen Krankheiten
Juvalta, S., Altwicker-Hámori, S., & Rüesch, P. (2018) · Informationszentrum Lebenswissenschaften (ZB MED) · doi:10.4126/frl01-006409965
Metadata
- Authors
- Golubchik, P., Sever, J., Zalsman, G., & Weizman, A.
- Affiliations
- Geha Mental Health Center (IL)
- Tel Aviv University (IL)
- Corresponding author
- Golubchik, Pavel
- Venue
- International Clinical Psychopharmacology
- Published
- 2008-07
- Volume
- 23
- Issue
- 4
- Pages
- 228-231
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W2034420993
- Cited by
- 36
- References
- 22
- Citations by year
- 2025: 2 · 2024: 1 · 2023: 2 · 2021: 4 · 2020: 2 · 2019: 3 · 2018: 2 · 2017: 2 · 2016: 1 · 2015: 1 · 2014: 3 · 2013: 2 · 2012: 3
- FWCI
- 1.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Social Sciences › Psychology › Clinical Psychology › Personality Disorders and Psychopathology
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- methylphenidate, attention deficit hyperactivity disorder, borderline personality disorder, adolescent girls, aggression, tolerability
- MeSH terms
- Adolescent, Adult, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Borderline Personality Disorder, Female, Humans, Methylphenidate, Prospective Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.